Dashboard
Manage Tickers

MIRM


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cantor-fitzgerald-maintains-overweight-on-mirum-pharmaceuticals-raises-price-target-to-60
Cantor Fitzgerald Maintains Overweight on ...
08/08/2024 14:46:30

Cantor Fitzgerald analyst Josh Schimmer maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price...

evercore-isi-group-maintains-outperform-on-mirum-pharmaceuticals-raises-price-target-to-66
Evercore ISI Group Maintains Outperform on...
08/08/2024 13:10:12

Evercore ISI Group analyst Gavin Clark-Gartner maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises th...

baird-maintains-outperform-on-mirum-pharmaceuticals-raises-price-target-to-44
Baird Maintains Outperform on Mirum Pharma...
08/08/2024 11:59:05

Baird analyst Brian Skorney maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from...

mirum-pharmaceuticals-on-track-to-achieve-fy24--global-net-product-sales-guidance-of-310m---320m
Mirum Pharmaceuticals On Track To Achieve ...
08/07/2024 21:31:23

mirum-pharmaceuticals-q2-2024-gaap-eps-052-misses-047-estimate-sales-77875m-beat-75246m-estimate
Mirum Pharmaceuticals Q2 2024 GAAP EPS $(0...
08/07/2024 20:20:50

Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate ...

watching-mirum-pharmaceuticals-shares-trading-higher-after-circulation-of-unconfirmed-rumor-that-swedish-orphan-biovitrum-ab-sobi-has-proposed-a-takeover
Watching Mirum Pharmaceuticals; Shares Tra...
07/26/2024 19:19:44

hc-wainwright--co-reiterates-buy-on-mirum-pharmaceuticals-maintains-66-price-target
HC Wainwright & Co. Reiterates Buy on Miru...
07/26/2024 11:20:09

HC Wainwright & Co. analyst Ed Arce reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and maintains $66 price ta...

mirums-livmarli-now-approved-for-progressive-familial-intrahepatic-cholestasis-in-patients-12-months-and-older
Mirum's LIVMARLI Now Approved For Progress...
07/25/2024 12:33:20

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a label...

Core News & Articles
Janus Henderson Group Discloses 10.6% Pass...
07/10/2024 17:18:09

- Form 13G

hc-wainwright--co-reiterates-buy-on-mirum-pharmaceuticals-maintains-66-price-target
HC Wainwright & Co. Reiterates Buy on Miru...
07/08/2024 17:54:19

HC Wainwright & Co. analyst Ed Arce reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and maintains $66 price ta...

mirum-pharmaceuticals-livmarli-approved-in-the-eu-for-patients-with-pfic-in-patients-3-months-of-age-and-older
Mirum Pharmaceuticals' LIVMARLI Approved I...
07/08/2024 12:38:45

European Commission grants LIVMARLI marketing authorization for treatment of PFIC in patients three months and older.Approval f...

hc-wainwright--co-reiterates-buy-on-mirum-pharmaceuticals-maintains-66-price-target
HC Wainwright & Co. Reiterates Buy on Miru...
06/28/2024 17:26:22

HC Wainwright & Co. analyst Ed Arce reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and maintains $66 price ta...

mirum-submits-new-drug-application-to-fda-for-chenodiol-for-treatment-of-ctx
Mirum Submits New Drug Application To FDA ...
06/28/2024 12:36:22

Submission based on the positive Phase 3 RESTORE studyMirum holds orphan designation for chenodiol in CTXPotential to have firs...

stifel-maintains-buy-on-mirum-pharmaceuticals-raises-price-target-to-66
Stifel Maintains Buy on Mirum Pharmaceutic...
06/20/2024 13:22:57

Stifel analyst Dae Gon Ha maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $48 to $66.

citigroup-maintains-buy-on-mirum-pharmaceuticals-raises-price-target-to-64
Citigroup Maintains Buy on Mirum Pharmaceu...
06/18/2024 14:43:01

Citigroup analyst David Lebowitz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $...

jp-morgan-maintains-overweight-on-mirum-pharmaceuticals-raises-price-target-to-39
JP Morgan Maintains Overweight on Mirum Ph...
06/18/2024 14:09:38

JP Morgan analyst Jessica Fye maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target fr...

nvidia-to-rally-around-53-here-are-10-top-analyst-forecasts-for-tuesday
Nvidia To Rally Around 53%? Here Are 10 To...
06/18/2024 13:44:27

morgan-stanley-maintains-overweight-on-mirum-pharmaceuticals-raises-price-target-to-57
Morgan Stanley Maintains Overweight on Mir...
06/18/2024 11:08:58

Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price targ...

jmp-securities-maintains-market-outperform-on-mirum-pharmaceuticals-raises-price-target-to-68
JMP Securities Maintains Market Outperform...
06/18/2024 10:53:09

JMP Securities analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and raises t...

why-ovid-therapeutics-shares-are-trading-lower-by-19-here-are-other-stocks-moving-in-mondays-mid-day-session
Why Ovid Therapeutics Shares Are Trading L...
06/17/2024 17:21:47

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION